Valuation
- Market cap
- 7,794,000
- Revenue TTM
- $0
- Net income TTM
- $-4,230,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 2,700
- Avg volume
- 19,934
- Day's range
- $4.59 – $5.10
- Shares out
- 1,568,000
- Stochastic %K
- 43%
- Beta
- -2.89
- Analysts
- Strong Buy
- Price target
- —
Company profile
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to C...
Show more
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 718 673 6078
- Website
- https://www.curanexpharma.com
- Address
- 2 Jericho Plaza, Suite 101B, Jericho, United States
Latest news
No headlines yet.
